UPDATE 1-Galenica to buy biotech firm Relypsa for $1.5 bln before break-up

July 21 (Reuters) - Galenica has agreed to buy U.S.

biotech firm Relypsa for $1.53 billion in cash to

strengthen its Vifor Pharma unit ahead of splitting up the Swiss

healthcare group.

Read more